Zentalis Pharmaceuticals Inc (NASDAQ:ZNTL) shares, rose in value, with the stock price down by -0.07% to the previous day’s close as strong demand from buyers drove the stock to $1.76.
Actively observing the price movement in the recent trading, the stock is buoying the session at $1.76, falling within a range of $1.74 and $2.01. Referring to stock’s 52-week performance, its high was $16.26, and the low was $1.61. On the whole, ZNTL has fluctuated by -18.20% over the past month.
With the market capitalization of Zentalis Pharmaceuticals Inc currently standing at about $125.34 million, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-Mar-25.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that ZNTL’s technical picture suggests that short-term indicators denote the stock is a 100% Sell on average. However, medium-term indicators have put the stock in the category of 100% Sell while long-term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the price of ZNTL currently trading nearly -5.57% and -14.50% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 41.16, while the 7-day volatility ratio is showing 7.62% which for the 30-day chart, stands at 8.51%. Furthermore, Zentalis Pharmaceuticals Inc (ZNTL)’s beta value is 1.77, and its average true range (ATR) is 0.18.
A comparison of Zentalis Pharmaceuticals Inc (ZNTL) with its peers suggests the former has fared considerably weaker in the market. ZNTL showed an intraday change of -0.07% in today’s session so far, and over the past year, it shrunk by -87.05%%.
Data on historical trading for Zentalis Pharmaceuticals Inc (NASDAQ:ZNTL) indicates that the trading volumes over the past 10 days have averaged 0.81 and over the past 3 months, they’ve averaged 1.81 million. According to company’s latest data on outstanding shares, there are 71.15 million shares outstanding.
Nearly 24.81% of Zentalis Pharmaceuticals Inc’s shares belong to company insiders and institutional investors own 87.64% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 5.33 million shares as on 2025-03-14, resulting in a short ratio of 5.64. According to the data, the short interest in Zentalis Pharmaceuticals Inc (ZNTL) stood at 1505.00 of shares outstanding as of 2025-03-14; the number of short shares registered in 2025-02-14 reached 5.19 million. The stock has fallen by -41.96% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the ZNTL stock heading into the next quarter.
